◎ Sugi Atlas

Atlas / Drug / Carfilzomib

Carfilzomib

drug
On this page

Also known as KyprolisNSC-758252PR-171SID124955654SID144206630SID170466878CARFILZOMIB (PR-171)

Summary

Carfilzomib (CHEMBL451887) is an approved protein antineoplastic agent (ATC L01XG02) targeting PSMB5; indicated across 31 conditions including plasma cell myeloma and neoplasm; with CIViC clinical evidence for 1 variant-indication association (e.g. PSMD4 Overexpression in colorectal cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: L01XG02
  • Targets: 1 (PSMB5)
  • Indications: 31 conditions
  • Clinical trials: 222
  • Precision-oncology evidence (CIViC): 1 variant–indication association
  • Chemistry: 719.9 Da · C40H57N5O7

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL451887
NameCarfilzomib
TypeProtein
Max phase4
FDA approvedyes
PubChem CID11556711
ChEBICHEBI:65347
ATCL01XG02
Molecular formulaC40H57N5O7
Molecular weight719.9
InChIKeyBLMPQMFVWMYDKT-NZTKNTHTSA-N

SMILES: CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

IUPAC name: (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide

ChEBI definition: A synthetic tetrapeptide consisting of morpholin-4-acetyl, L-2-amino-4-phenylbutanoyl, L-leucyl and L-phenylalanyl residues joined in sequence with the C-terminus connected to the amino group of (2S)-2-amino-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-1-one via an amide linkage. Used for the treatment of patients with multiple myeloma

Pharmacological roles (ChEBI): antineoplastic agent, proteasome inhibitor.

Also known as: Carfilzomib, Kyprolis, NSC-758252, PR-171, CARFILZOMIB, SID124955654, SID144206630, SID170466878, carfilzomib, CARFILZOMIB (PR-171), Carfilzomib (PR-171)

Patent coverage: 4,848 distinct patent families (12,508 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PSMB5proteasome 20S subunit beta 5Inhibition8.2495% (common-essential)P28074

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Proteasome subunit beta type-9, Proteasome subunit beta type-6, Cytochrome P450 3A, 26S proteasome, Voltage-gated inwardly rectifying potassium channel KCNH2, Glutathione S-transferase omega-1, Proteasome subunit beta type-10, Proteasome subunit beta type-7, Proteasome Macropain subunit, 20S proteasome, Cathepsin B, Proteasome component C5, Proteasome Macropain subunit MB1, Proteasome subunit beta type-8.

Bioactivity

ChEMBL activities: 42 potent at pChembl ≥ 5 of 47 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PSMB58.68IC502.1nMCHEMBL_ACT_24866232
PSMB58.57IC502.7nMCHEMBL_ACT_19218654
PSMB88.49IC503.2nMCHEMBL_ACT_24866180
PSMB58.3IC505nMCHEMBL_ACT_18940519
PSMB58.3IC505nMCHEMBL_ACT_25964122
PSMB58.22IC506nMCHEMBL_ACT_19258354
PSMB58.22IC506nMCHEMBL_ACT_24972783
PSMB58.15IC507nMCHEMBL_ACT_19300182
PSMB118.15IC507nMCHEMBL_ACT_23242468
PSMB58.08IC508.4nMCHEMBL_ACT_16775820
PSMB58.08IC508.4nMCHEMBL_ACT_18008073
PSMB58.08IC508.4nMCHEMBL_ACT_22438475
PSMB118.07IC508.6nMCHEMBL_ACT_14660982
PSMB58.07IC508.6nMCHEMBL_ACT_19365872
PSMB118.07IC508.6nMCHEMBL_ACT_19365888
PSMB58.02IC509.6nMCHEMBL_ACT_18807401
PSMB107.89IC5013nMCHEMBL_ACT_24866175
PSMB87.85IC5014nMCHEMBL_ACT_2529500
PSMB117.77IC5017nMCHEMBL_ACT_25524933
PSMB57.63IC5023.6nMCHEMBL_ACT_19228965
PSMB87.57IC5027nMCHEMBL_ACT_18940562
PSMB87.49IC5032.6nMCHEMBL_ACT_18807312
PSMB87.48IC5033nMCHEMBL_ACT_19258361
PSMB87.47IC5034nMCHEMBL_ACT_19365869
PSMB77.37IC5043nMCHEMBL_ACT_24866227
PSMB97.16IC5069nMCHEMBL_ACT_24866170
GSTO16.82IC50150nMCHEMBL_ACT_18550661
PSMB26.69IC50203nMCHEMBL_ACT_18807419
PSMB116.57IC50269.8nMCHEMBL_ACT_23242469
CYP3A46.31IC50490nMCHEMBL_ACT_15448843
PSMB106.21IC50620nMCHEMBL_ACT_19258350
PSMB26.08IC50825nMCHEMBL_ACT_18940509
PSMB66.05IC50890nMCHEMBL_ACT_24866222
PSMB115.98IC501050nMCHEMBL_ACT_25524943
PSMB15.84IC501452nMCHEMBL_ACT_18940514
PSMB25.74IC501812nMCHEMBL_ACT_19365866
PSMB15.62IC502400nMCHEMBL_ACT_19258334
PSMB95.62IC502420nMCHEMBL_ACT_19258340
PSMB15.62IC502400nMCHEMBL_ACT_24972773
PSMB95.53IC502940nMCHEMBL_ACT_19218663
PSMB25.44IC503600nMCHEMBL_ACT_19258344
PSMB25.44IC503600nMCHEMBL_ACT_24972777

Target pathways

Aggregated over 1 target gene(s): PSMB5.

Top Reactome pathways

68 total, by targets touching each:

PathwayTargetsGenes
Activation of NF-kappaB in B cells1PSMB5
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha1PSMB5
ER-Phagosome pathway1PSMB5
Cross-presentation of soluble exogenous antigens (endosomes)1PSMB5
Autodegradation of Cdh1 by Cdh1:APC/C1PSMB5
SCF-beta-TrCP mediated degradation of Emi11PSMB5
APC/C:Cdc20 mediated degradation of Securin1PSMB5
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G11PSMB5
Cdc20:Phospho-APC/C mediated degradation of Cyclin A1PSMB5
Vpu mediated degradation of CD41PSMB5
Vif-mediated degradation of APOBEC3G1PSMB5
SCF(Skp2)-mediated degradation of p27/p211PSMB5
Degradation of beta-catenin by the destruction complex1PSMB5
Downstream TCR signaling1PSMB5
Regulation of activated PAK-2p34 by proteasome mediated degradation1PSMB5
Separation of Sister Chromatids1PSMB5
FCERI mediated NF-kB activation1PSMB5
Autodegradation of the E3 ubiquitin ligase COP11PSMB5
Regulation of ornithine decarboxylase (ODC)1PSMB5
ABC-family protein mediated transport1PSMB5
AUF1 (hnRNP D0) binds and destabilizes mRNA1PSMB5
Asymmetric localization of PCP proteins1PSMB5
Degradation of AXIN1PSMB5
Degradation of DVL1PSMB5
Hedgehog ligand biogenesis1PSMB5
Hh mutants are degraded by ERAD1PSMB5
Dectin-1 mediated noncanonical NF-kB signaling1PSMB5
CLEC7A (Dectin-1) signaling1PSMB5
Degradation of GLI1 by the proteasome1PSMB5
Degradation of GLI2 by the proteasome1PSMB5
GLI3 is processed to GLI3R by the proteasome1PSMB5
Hedgehog ‘on’ state1PSMB5
Regulation of RAS by GAPs1PSMB5
TNFR2 non-canonical NF-kB pathway1PSMB5
NIK–>noncanonical NF-kB signaling1PSMB5
Defective CFTR causes cystic fibrosis1PSMB5
MAPK6/MAPK4 signaling1PSMB5
UCH proteinases1PSMB5
Ub-specific processing proteases1PSMB5
Assembly of the pre-replicative complex1PSMB5
Orc1 removal from chromatin1PSMB5
CDK-mediated phosphorylation and removal of Cdc61PSMB5
G2/M Checkpoints1PSMB5
Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A1PSMB5
Ubiquitin-dependent degradation of Cyclin D1PSMB5
The role of GTSE1 in G2/M progression after G2 checkpoint1PSMB5
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis1PSMB5
RUNX1 regulates transcription of genes involved in differentiation of HSCs1PSMB5
Regulation of RUNX2 expression and activity1PSMB5
Regulation of RUNX3 expression and activity1PSMB5

Dominant GO biological processes

GO termTargets
proteolysis1
response to oxidative stress1
proteasomal ubiquitin-independent protein catabolic process1
proteasome-mediated ubiquitin-dependent protein catabolic process1
proteasome assembly1
obsolete proteolysis involved in protein catabolic process1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
plasma cell myeloma4MONDO:0009693EFO:0001378
neoplasm4MONDO:0005070EFO:0000616

25 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
lymphoma2MONDO:0005062EFO:0000574
mantle cell lymphoma2MONDO:0018876EFO:1001469
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
Waldenstrom macroglobulinemia2MONDO:0100280EFO:0009441
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
kidney cancer2MONDO:0002367MONDO:0002367
follicular lymphoma2MONDO:0018906MONDO:0018906
smoldering plasma cell myeloma2MONDO:0005235EFO:0003073
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
leukemia1MONDO:0005059EFO:0000565
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
peripheral T-cell lymphoma, not otherwise specified1MONDO:0004964EFO:0000211
diffuse large B-cell lymphoma1MONDO:0018905EFO:0000403
small cell lung carcinoma1MONDO:0008433EFO:0000702
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
Sezary syndrome1MONDO:0017844EFO:1000785
mycosis fungoides1MONDO:0009691EFO:1001051
amyloidosis1MONDO:0019065EFO:1001875
Hodgkins lymphoma1MONDO:0004952EFO:0000183
plasma cell leukemia1MONDO:0018689EFO:0006475
plasmacytoma1MONDO:0005615EFO:0006738
prolymphocytic leukemia1MONDO:0001023MONDO:0001023
acute myeloid leukemia1MONDO:0018874EFO:0000222
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
non-small cell lung carcinoma1MONDO:0005233EFO:0003060

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 222.

Phase distribution

PhaseTrials
PHASE284
PHASE151
PHASE1/PHASE247
PHASE328
Not specified9
PHASE42
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06409702PHASE4RECRUITINGTreatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT03416374PHASE4COMPLETEDA Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
NCT01863550PHASE3ACTIVE_NOT_RECRUITINGBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT02659293PHASE3ACTIVE_NOT_RECRUITINGTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
NCT03651128PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03729804PHASE3ACTIVE_NOT_RECRUITINGCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03742297PHASE3ACTIVE_NOT_RECRUITINGTreatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
NCT03948035PHASE3ACTIVE_NOT_RECRUITINGElotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
NCT04096066PHASE3ACTIVE_NOT_RECRUITINGA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
NCT05438043PHASE3RECRUITINGA Study of Daratumumab
NCT05552976PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05572515PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT06152575PHASE3RECRUITINGMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06158841PHASE3RECRUITINGStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06413498PHASE3RECRUITINGA Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06615479PHASE3RECRUITINGA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT07222761PHASE3RECRUITINGA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07391657PHASE3RECRUITINGA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07555938PHASE3RECRUITINGCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT01080391PHASE3COMPLETEDStudy Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
NCT01302392PHASE3COMPLETEDA Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
NCT01568866PHASE3COMPLETEDPhase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
NCT01818752PHASE3COMPLETEDPhase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
NCT02412878PHASE3COMPLETEDOnce-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
NCT03029234PHASE3COMPLETEDCarfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
NCT03158688PHASE3COMPLETEDStudy of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
NCT03275285PHASE3COMPLETEDMultinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
NCT03859427PHASE3COMPLETEDA Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT05675319PHASE3TERMINATEDAllogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT06232707PHASE3WITHDRAWNA Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT01297764PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01559935PHASE2ACTIVE_NOT_RECRUITINGCarfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
NCT02343042PHASE1/PHASE2ACTIVE_NOT_RECRUITINGSelinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02415413PHASE2ACTIVE_NOT_RECRUITINGCarfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
NCT02773030PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02899052PHASE2ACTIVE_NOT_RECRUITINGStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
NCT03004287PHASE2ACTIVE_NOT_RECRUITING2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
NCT03104842PHASE2ACTIVE_NOT_RECRUITINGEvaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
NCT03289299PHASE2ACTIVE_NOT_RECRUITINGAggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03290950PHASE2ACTIVE_NOT_RECRUITINGA Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
NCT03314636PHASE2ACTIVE_NOT_RECRUITINGIntensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
NCT03500445PHASE2ACTIVE_NOT_RECRUITINGDaratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
NCT03556332PHASE2ACTIVE_NOT_RECRUITINGA Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
NCT03606577PHASE2ACTIVE_NOT_RECRUITINGAn Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
NCT03673826PHASE2ACTIVE_NOT_RECRUITINGCarfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
NCT03756896PHASE2ACTIVE_NOT_RECRUITINGCarfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
NCT03815279PHASE2ENROLLING_BY_INVITATIONA Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
NCT03989414PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT04176718PHASE2RECRUITINGDaratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04263480PHASE2ACTIVE_NOT_RECRUITINGEfficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström’s Macroglobulinemia
NCT04268498PHASE2ACTIVE_NOT_RECRUITINGA Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04430894PHASE2ACTIVE_NOT_RECRUITINGKRDI in Transplant-Eligible MM
NCT04756401PHASE2ACTIVE_NOT_RECRUITINGSelinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
NCT04764942PHASE1/PHASE2ACTIVE_NOT_RECRUITINGSelinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
NCT04822337PHASE1/PHASE2ACTIVE_NOT_RECRUITINGStudy of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04850599PHASE2ACTIVE_NOT_RECRUITINGIsatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04883242PHASE2ACTIVE_NOT_RECRUITINGIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04925193PHASE2ACTIVE_NOT_RECRUITINGPersonalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
NCT04933539PHASE2ACTIVE_NOT_RECRUITINGSubcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
NCT04973605PHASE1/PHASE2RECRUITINGA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT05017545PHASE1/PHASE2ACTIVE_NOT_RECRUITINGCarfilzomib and Belatacept for Desensitization
NCT05060627PHASE1/PHASE2ACTIVE_NOT_RECRUITINGStudy of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
NCT05199311PHASE1/PHASE2RECRUITINGCarfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
NCT05434689PHASE1/PHASE2ACTIVE_NOT_RECRUITINGCOMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05497804PHASE2ACTIVE_NOT_RECRUITINGCombination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
NCT05669989PHASE2ACTIVE_NOT_RECRUITINGInternational Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
NCT05704049PHASE2ACTIVE_NOT_RECRUITINGA Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05789303PHASE2RECRUITINGStudy of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
NCT05896228PHASE2RECRUITINGIberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
NCT05909826PHASE2NOT_YET_RECRUITINGCarfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
NCT06140966PHASE2RECRUITINGStudy to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
NCT06356571PHASE2RECRUITINGA Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06627751PHASE2RECRUITINGMezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
NCT06892522PHASE1/PHASE2RECRUITINGA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
NCT06948084PHASE2NOT_YET_RECRUITINGTesting the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
NCT07227311PHASE2RECRUITINGA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07463807PHASE1/PHASE2NOT_YET_RECRUITINGTesting the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
NCT07479979PHASE1/PHASE2RECRUITINGStudy of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT07605416PHASE2NOT_YET_RECRUITINGTesting an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
NCT00511238PHASE2COMPLETEDPhase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
NCT00530816PHASE2COMPLETEDPhase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
NCT00531284PHASE1/PHASE2COMPLETEDPhase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
NCT00721734PHASE2COMPLETEDStudy of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
NCT00884312PHASE2COMPLETEDA Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
NCT01029054PHASE1/PHASE2COMPLETEDCarfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT01057225PHASE1/PHASE2COMPLETEDCyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
NCT01246063PHASE1/PHASE2COMPLETEDCarfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01279694PHASE1/PHASE2COMPLETEDTrial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
NCT01346787PHASE2COMPLETEDCarfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
NCT01351623PHASE2COMPLETEDInfusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
NCT01402284PHASE2COMPLETEDCarfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01464034PHASE1/PHASE2TERMINATEDA Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT01470196PHASE2COMPLETEDCarfilzomib, Rituximab and Dexamethasone in Waldenstrom’s Macroglobulinemia
NCT01496118PHASE1/PHASE2COMPLETEDStudy of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
NCT01572480PHASE2COMPLETEDCarfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01658904PHASE1/PHASE2TERMINATEDCarfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
NCT01665794PHASE1/PHASE2COMPLETEDCarfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01677858PHASE1/PHASE2COMPLETEDA Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
NCT01690143PHASE1/PHASE2COMPLETEDCarfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
NCT01775553PHASE2COMPLETEDStudy of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
PSMD4 OverexpressionColorectal CancerSensitivity/ResponseCarfilzomibCIViC DEID7330

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 4 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

12 molecules share ≥1 primary target. Top 12 by shared-target count:

MoleculeSourceStatusShared targets
BORTEZOMIBChEMBLPhase 4 (approved)PSMB5
IXAZOMIBChEMBLPhase 4 (approved)PSMB5
VINBLASTINEChEMBLPhase 4 (approved)PSMB5
CURCUMINChEMBLPhase 3PSMB5
EPIGALOCATECHIN GALLATEChEMBLPhase 3PSMB5
MARIZOMIBChEMBLPhase 3PSMB5
QUERCETINChEMBLPhase 3PSMB5
DELANZOMIBChEMBLPhase 2PSMB5
GENISTEINChEMBLPhase 2PSMB5
LUTEOLINChEMBLPhase 2PSMB5
OPROZOMIBChEMBLPhase 2PSMB5
ZETOMIPZOMIBChEMBLPhase 2PSMB5

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot